<DOC>
	<DOCNO>NCT00941707</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , tolerability safety JNJ-38518168 compare placebo adult participant active rheumatoid arthritis ( long time systemic disease joint , mark inflammatory change synovial membrane bone ) despite methotrexate ( MTX ) therapy .</brief_summary>
	<brief_title>An Efficacy Safety Study JNJ-38518168 Adult Participants With Rheumatoid Arthritis</brief_title>
	<detailed_description>This multi-center ( 1 hospital medical school team work medical research study ) , randomize ( study drug assign chance ) , double-blind ( neither physician participant know treatment participant receives ) , placebo-controlled ( inactive substance ; pretend treatment [ drug ] compare clinical trial drug test drug real effect ) parallel-group ( group participant treat time ) study . The study consist 3 phase ; Screening phase ( 3 week ) , Treatment phase ( 12 week ) Follow-up phase ( 4 week ) . Each participant enrol study approximately 19 week . Participants active rheumatoid arthritis despite MTX therapy receive JNJ-38518168 , 100 milligram ( mg ) per day match placebo capsule daily 12 week . Efficacy primarily evaluate change Baseline disease activity index score C-reactive protein Week 12 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Participants diagnose rheumatoid arthritis ( RA ) accord revise 1987 criterion ARA ( Arnett et al , 1988 ) least 6 month Screening Participants treat tolerated methotrexate ( MTX ) treatment dosages 7.5 25 milligram ( mg ) per week inclusive , minimum 4 month Screening Participants use nonsteroidal antiinflammatory drug ( NSAIDs ) analgesic ( drug use control pain ) regularly RA , participant must stable dose least 2 week first dose study medication Participants use oral corticosteroid ( compound , usually hormonal , take orally [ mouth ] order block ovulation [ discharge egg ovary ] prevent occurrence pregnancy [ carry unborn baby ] ) , must stable dose less equal 10 mg per day prednisone another oral corticosteroid least 4 week first dose study medication continue dose throughout study . If use corticosteroid study initiation , participant must receive oral corticosteroid least 4 week first dose study medication Participants currently treat folic acid minimum dose 5 mg per week Participants inflammatory disease RA Participant use follow medication : Dpenicillamine , hydroxychloroquine , chloroquine , oral parenteral gold salt , sulfasalazine , leflunomide , azathioprine , cyclosporine , tacrolimus , mycophenolatemofetil Participant receive intraarticular , intramuscular ( muscle ) , intravenous ( vein ) corticosteroid , include adrenocorticotropic hormone ( hormone make brain activate adrenal gland ) within 4 week first dose study medication Participants treat investigational drug medical device within 4 week 5 halflives drug , whichever long first dose study medication Participants undergone surgical treatment RA include synoviectomy ( surgical removal part synovial membrane joint ) arthroplasty ( surgery fix joint ) within 3 month first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>JNJ-38518168</keyword>
</DOC>